Entremed - Biotechwert mit riesigem Potential - 500 Beiträge pro Seite

[Boersi]

Entremed ist m. E. ein sehr interessantes Unternehmen, daß mittlerweile eine Menge hochrangiger Partner an sich gebunden hat u. a. Brystl Meyers Squibb, Celgene, Chiron Corporation, Covance Biotechnology Services.

Cash reicht bis 2005. Mehrere Wirkstoffe in Phase I und Phase II. Lizenzeinahmen jetzt schon während den Testphasen. Panzem - ein Wirkstoff mit riesigem Potential, unter anderem gegen Krebs (Phase II)!



http://www.entremed.com/pipeline/manufacturing.cfm


Übersicht über die einzelnen Testphasen im Detail

http://www.entremed.com/media/alltrials.cfm







Unglaubliches Umsatzvolumen seit ca. 1 Monat:





Finde Entremed hochinteressant. Hier noch sämtliche News bis zurück nach 1996:

http://investor.entremed.com/ireye/ir_site.zhtml?ticker=ENMD…

[kaiser23]

Super dann nimm lieber virologic, hat bessere produkte in der pipline und übrigens es bibt noch eine Phase III und ..., die Gefahr ist doch ziemlich groß findest du nicht......

[Boersi]

@kaiser23

Das Investment scheint auf den esten Blick hochspekulativ, nach der letzten Kapitalerhöhung hat Entremed nun jedoch Cash bis 2005! Dies birgt schon einiges an Sicherheit.

Außerdem ist es bis dahin noch lange hin, d. h. es kann noch einige größere Überraschungen geben in hinsicht auf die Meilensteins- und Lizenzzahlungen.

Virologic kenne ich nur vom Chart, habe dort noch nicht recherchiert. Für mich ist jedoch wichtig, daß Kontakte zu den großen und größeren der Branche schon fester Bestandteil der Firmenstrategie.

[kaiser23]

das ist auch vollkommen richtig, tue mir einen gefallen und prüfe virologic dann wirst du was feststellen was du von dieser Aktie auch gedacht hast nur Virologic hat mehr Wachstumspotential...., meine Meinung

[Boersi]

Würde mir gerne mal die HP von Virologic ansehen, die ist jedoch derzeit wohl offline

http://www.virologic.com/

[globalguru]

@Boersi

ich würde an Deiner stelle noch abwarten. Die guten News der letzten Tage stehen in engem Zusammenhang mit den beiden letzten KE - das sollte zu denken geben. Wie ich im anderen Thread schon geschildert habe wird das nicht die letzte KE sein und statt der von Dir prophezeiten guten News können auch schlechte kommen - siehe endostatin und angiostatin
Ansonsten bin ich vorsichtig optimistisch gestimmt, obwohl ich mir mit ENMD schon mächtig die Finger verbrannt habe. Gut möglich das der Wert sich wieder bei 1-2$ einpendelt, dann werde ich wieder einsteigen.

gruß

[kaiser23]

nee hier http://www.cytovision.com/, ist sie nicht suche weiter, schaue dir diese aktie mal genauer an sehr interessant... nur zu info was du damit machst ist dein problem

[Boersi]

@kaiser23

... so ein Durcheinander! Was willst Du eigentlich???


@globalguru

Genauso gut kann es jetzt bald zügig wieder richtung 4 $ gehen. Für mich ist da was im Busch. Sieh Dir mal die Umsätze an, die wahren schon seit vielen Jahren nicht mehr so hoch!

[kaiser23]

Sorry hast recht ist momentan offline daher wollt ich auf diese Aktie aufmerksam machen....903769

[Boersi]

@kaiser23

Ist ja ganz nett, daß Du mir deine Lieblinge aufzeigen willst. Würde Dich jedoch bitten einfach einen neuen Thread für die neuen Werte aufzumachen, dann können wir weiter diskutieren! Danke.

[globalguru]

@Boersi

möglich ist alles. ENMD ist eine Wette. Entweder Riesengewinn oder Totalverlust.
Und bitte sei nicht so blauäugig. Den Busch in dem was ist, haben die vermutlich selber inszeniert da die Kohle gebraucht wurde.

gruß

[Boersi]

@Globalguru

Danke für den Hinweis.

Weisst Du wann die ersten Lizenzeinnahmen bez. des folgenden Wirstoffes an Entremed einfließen?

ENMD 0995** Mayo Clinic, Rochester, MN Dr. Martha Lacy Multiple myeloma Phase I

**ENMD 0995 was licensed to Celgene in a December 31, 2002 transaction. Currently, EntreMed is managing the trial.

[Boersi]

Was auch interessant ist, daß einige Testversuche mit Entremeds Wirkstoffen von dem National Cancer Institute gesponsored werden, d. h. dafür laufen keine Kosten auf.

Wirkstoffe die das betrifft sind:

Panzem™*
Endostatin*


*NCI-sponsored trial. EntreMed provides only the study drug for this trial.

[globalguru]

@Boersi

ich weiß nichts genaues, da ich ENMD vor Monaten verkauft habe und nur noch gelegentlich beobachte.
Ich glaube, das der Rechtsstreit mit Celgene beigelegt wurde und eine Lizenzzahlung von ca. 19Mill€ vereinbart wurde. Wann das Geld fließt, oder ob es schon geflossen ist weiß ich nicht. Schau doch mal in die Bilanzen 2001, 2002, oder besser noch Q1, da müßte es ausgewiesen sein.

gruß

[globalguru]

@Boersi

soviel wie ich weiß, konzentriert sich ENMD aus Kostengründen zur Zeit nur auf Panzem, weil die Versuche mit Endostatin und Angiostatin sich in der Sackgasse befinden - sprich keine nennenswerten Erfolge erzielt worden sind.

gruß

[Boersi]

Da hab ich bisher nix gefunden, ich gehe davon aus, da die 23 mio $ noch fliessen werden.

Denke Entremed hat gute Chancen den Turnaround nun zu schaffen. Was ich aus älteren Threads immer gelesen habe, daß die meisten Anlegen sich große Sorgen über die finanzielle Zukunft um Entremed gemacht hatten. Dieses Problem wurde erst vor ein paar Tagen aus der Welt geschafft. Hier könnte ich mir auch vorstellen, daß da einige andere Investoren nun auch so denken und wieder einsteigen werden. Es kommt wieder mehr Sicherheit in den Wert.

[globalguru]

Die finanzielle Basis sieht in der Tat nicht schlecht aus.
Aber in der Biotecbranche sind 2 Jahre garnichts. Hoffnungsvoll stimmt mich nur, dass die KE offenbar ausserbörslich mit Instis durchgezogen wurde. Die Testergebnisse mit Panzem müssen offensichtlich Erfolge erzielt haben(was wir kleinen natürlich nicht zu erfahren bekommen und wenn dann erst später), sonst hätten die keine Millionen investiert.

gruß

[Boersi]

@globalguru

Bin ganz Deiner Meinung. Ich für meinen Teil habe zu 2,5 € meine erste Position in Entremed aufgebaut. Sollte sich der Aufwärtstrend nachhaltig bestätigen, werde ich nachlegen. Allein um den langfristigen Trendkanal zu bestätigen zu bestätigen, sind exorbitante Steigerungen möglich.

@kaiser23

hab mir kurz, aber wirklich nur kurz die nun wieder funktionierende HP von Virologic angesehen. Kann Dir aber nicht zustimmen. Virologic hat zwar schon jede menge fertig entwickelte Produkte, dies sind meist nur div. Tests für HIV. Finde die Produktpalette wenig phantasiereich im gegensatz zu dem was Entremed zu bieten hat. Wie siehts denn mit großen Partnern aus. Hab da auf die schnelle nix gefunden. Erster Eindruck: Virologic nicht kaufen - Entremed erste Position aufbauen.

[globalguru]

@Boersi

#16
es sind nicht 23Mill€ sondern 27Mill€. Laut der nachfolgenden Quelle hat ENMD von Celgene eine Barzahlung + Vorzugsaktien erhalten. Außerdem wurden Meilensteinzahlungen vereinbart. Leider wurde nicht mitgeteilt, wie sich welche Beträge aufteilen.

gruß

ROCKVILLE, Md., April 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a biopharmaceutical leader in angiogenesis research and product development, today announced that the standstill period pursuant to the Celgene agreement has ended effective Midnight, March 31, 2003. In addition, the Company is moving towards expanding its strategic partnership with Celgene. The partnership is being solidified to target drug discovery and validation in the areas of cancer and inflammation. Both companies may also perform research and preclinical development for each other regarding small molecules from their preclinical programs.

(Photo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Neil Campbell, EntreMed President and Chief Operating Officer, commented, "We continue to enjoy a progressive relationship with Celgene and look forward to working with them in the areas of drug discovery and development."

"We look forward to further developing our strategic relationship with EntreMed in areas of mutual interest," said Sol Barer, President and COO of Celgene.

On January 2, 2003, EntreMed announced that it licensed all rights to its thalidomide analog programs including, ENMD 0995 and ENMD 0997, to Celgene in a deal valued at $27 million. Celgene also received an exclusive worldwide license from Children``s Hospital, Boston to its thalidomide analog patent portfolio. In addition, EntreMed is transferring to Celgene other assets and intellectual property with respect to thalidomide analogs developed by EntreMed. In return, EntreMed received cash payments and equity investments in the form of convertible preferred stock and warrants. Furthermore, Celgene assumed certain EntreMed license payment obligations and will have the option, for one year, to select one of three preclinical products for a research and development collaboration with and licensing opportunity from EntreMed.

[Mr.Arrogance]

globalguru, das ist nicht richtig.

die vorzugsaktien bzw. wandelanleihen hat CELG erhalten gegen zahlung von 16,75 mio $.
näheres dazu im thread Thread: 15.07.02 kaufe CELG

mr.A

[globalguru]

Mr.Arrogance

Du hast natürlich recht. Ich hatte ENMD und damit auch Celgene die letzten Monate nicht mehr im Focus.
Vielleicht kannst Du als Celgene Spezi auch ab und zu einen Beitrag im ENMD-Board machen. So wie die Sache aussieht hält ja Celgene mehrere Mill. Shares an ENMD.
Gut möglich das Celgene auch bei den letzten KE von ENMD dabei war. Hast Du nähere Infos?

gruß

[Boersi]

Bin wieder back in town (Italy Urlaub). Und siehe da, Entremed entwickelt sich prächtig:



Schlukurs 4.65 $ am Freitag. M. E. wird jetzt wieder durchgestartet.

[kurttilly]

Hallo zusammen!



Weiß jemand näheres warum Entremed jetz durchstartet??

mfg

kurttilly

[Boersi]

@kurttilly

Aufgrund des hohen und gleichbleibenden Umsatzes der letzten Monate, gehe ich davon aus, das einige Fonds sich generell die Biotech Branche als Investment ausgesucht haben. Da werden m. E. bevorzugt Firmen genommen, die für die nächsten Jahre einen gesichertes Cashpolster besitzen und auch noch Partnerschaften zu hochkarätigen Pharmas vorzeigen können.

Auch interessant ist:

Curis, siehe auch Thread: Curis - Heilungschance bei Krebs - Kurs explodiert ...

[Boersi]

Chart ist Top, wer noch einsteigen will sollte nun zugreifen. Ich denke, für den spekulativen Investor bieten sich bei den derzeitgen Rücksetzern attraktive Einstiegsmöglichkeiten. Wenn der Gesamtmarkt mitspielt, kann die Biotechrally noch ein wenig weitergehen.

Gefährlicher Verkaufdruck ist nicht zu erkennen, da die Umsätze mit den sinkenden Kursen drastisch kleiner werden.
Würde so um die 4,5 $ Limit setzen. Ob die jedoch vorerst noch erreicht werden????

[tandill]

Limit locker durchschlagen. Bald wieder bei 1€?

mfg

[globalguru]

@tandill

nicht unwahrscheinlich. Unter 2€ kauf ich ENMD wieder.
Die letzen kurstreibenden News waren eigentlich keine.
Erst wenn Phase III für ein Produkt erreicht wird, kann es interessant werden.

gruß

[Guru-Schreck]

auf island stehen gerade 30000 Stück als Kauforder für 4,3 $

[Boersi]

Glaube nicht, daß du ENMD noch für 2 $ bekommen wirst

[globalguru]

abwarten!
Es werden auch schlechte News kommen. Dann wird eingesammelt.

gruß

[Boersi]

Was für schlechte News soll´´n denn Deiner Meinung nach kommen? Cash ist kein Thmema mehr bis 2005 !

Gruß

[globalguru]

@Boersi

bis jetzt wurde nur die gute Verträglichkeit der Drogenanwärter nachgewiesen. Durchschlagende Heilungserfolge (bis auf Ausnahmen) wurden noch nicht erzielt. Wenn also die Phase 3 nicht kommt, sieht es düster aus.

gruß

[Guru-Schreck]

Krebsmedikament vor dem Durchbruch (20.05.2003)


Von einer Genentech-Meldung vom Vortag, die überraschenden Erfolge mit einem Krebspräparat beinhaltet, profitieren konnte auch die kleine Biotech-Schmiede Entremed (WKN 901417), wie der „Global Biotech Daily“ berichtet. Das experimentelle Medikament "Avastin", das am Montag diese Ergebnisse brachte, bekämpft Krebs, indem es dem Tumor die Blutversorgung abschneidet. Genau diesen Ansatz verfolgt auch Entremed und könnte damit den Schlüssel für die Krebstherapien der kommenden Jahre in der Hand halten! Einige spekulative Marktteilnehmer katapultierten den Titel bereits über 40 Prozent nach oben. Spekulative Anleger können bei dieser Wette auf den Durchbruch mitmischen. Im Wettlauf der mit Genentech und deren Forschungspartner Roche müssen sich zudem die übrigen Pharma- und Biotech-Allianzen schnell das nötige Knowhow einkaufen, um bei diesem lukrativen Geschäft nicht von Anfang an ins Hintertreffen zu geraten. Entremed ist mit einer aktuellen Market-Cap von 63 Millionen Dollar nur ein kleiner aber umso wichtiger Fisch. Und neben dem Knowhow hat Entremed noch weitere Krebspräparate in der klinischen Forschung.

Im vergangenen Jahr gab es die Aktie für unter einen Dollar, die Höchstkurse lagen im Jahr 2000 allerdings noch um 90 Dollar! Die Aktie ist allerdings nur für erfahrene Anleger geeignet. Und wegen des spekulativen Charakters wird empfohlen, nur eine kleine Position als Depotbeimischung aufzunehmen!


(aus: "Global Bitoech Daily" vom 20.05.03)

[tandill]

Irgendwie hat diese Meldung den Verkaufsdruck erhöht. Also keine positive Nachricht für ENMD.

mfg

[Boersi]

Jetzt ein kleiner Stimmungumschwung und die Bombe platzt



...schwach sinkender Kurs bei immer winziger werdendem Volumen!

[globalguru]

@boersi

sollten in der nächsten Zeit keine signifikanten News kommen, wird die 2$ Marke nocheinmal getestet. Dann werde auch ich wieder einsteigen.

gruß

[Boersi]

... na dann viel Spass beim warten.

Heute geht´s erst mal wieder rauf.

[Guru-Schreck]

Gibt es irgendwelche News oder ist nur der Käuferstreik beendet ?

[Boersi]

News hat´s wohl keine gegeben, sieht halt charttechnisch nach kaufen aus, weil billig! Wie heists so schön.... bei Rücksetzern nachkaufen

[globalguru]

@boersi

ENMD wird von Insidern getrieben. Ich bin sicher das es News gibt , sonst würde nicht so die Post abgehen. Viel Glück!

gruß

[schnirchel]

Danke börsi, für den Tip.
Sieht vielversprechend aus. Ich bin mit einer ersten Position eingestiegen und werde mal die Entwicklung abwarten. Wenn so ein Zug anfährt muß man seine Fahrkarte schon gelöst haben, sonst schaut man schnell hinterher.

[Boersi]

Schnirchel,

ganz mein Rede...Chart immer im Auge behalten!

Gruß

Boersi

[meislo]

Habe heute die aktuelle Ausgabe von Focus Money
gelesen. Hier wird Entremed als möglicher Kursvervielfacher beschrieben. Sollte sich Panzern (2, Klinische Phase) durchsetzten winken enorme Kursgewinne. Ab einer gewissen Grösse benötigen Tumore eigene Blutgefässe und hier würde Panzern erfolgreich den Tumor bekämpfen weil es eben die Bildung dieser Gefässe verhindert. Erfolgreich getestet wurde Panzern bei Brustkrebs, Prostatakrebs und Blutkrebs. Ausserdem befänden sich 3 weitere Produkte in Phase 2. Entremed würde ca. 35 Mio Dollar pro Jahr verbrauchen hätte aber erst kürzlich frisches Kapital von 18 Mio Dollar bekommen. Bei einer Börsenbewertung von 100 Mio. Dollar sei eine Kursvervielfachung möglich. Stoppkurs 3 Dollar


gruss meislo

[luto9]

Entremed AACR Studies Reveal Panzem(R)`s Action and Support Further Clinical Development
MONDAY, JULY 14, 2003 6:00 AM
- PR Newswire

ROCKVILLE, Md., Jul 14, 2003 /PRNewswire-FirstCall via COMTEX/ -- EntreMed, Inc. (ENMD) , a biopharmaceutical company focusing on the research and product development of small molecules, today announced preclinical data on Panzem(R) (2-methoxyestradiol or 2ME2), the Company`s lead clinical drug candidate, demonstrating its anti-cancer activity and lack of toxicity; findings that are instrumental to EntreMed`s scientists continued development of Panzem(R) and new chemical entities based on 2ME2-related structures. These data, compiled from three separate preclinical studies, were presented during the 94th Annual Meeting of the American Association for Cancer Research (AACR).

(Logo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Neil Campbell, EntreMed President and Chief Operating Officer, commented, "With our focus on small molecules, EntreMed will continue preclinical research to build on our understanding of Panzem(R)`s mechanisms of actions. With this mechanistic data, we can maximize Panzem(R)`s application in various indications within oncology and leverage its potential use in areas of medicine outside of oncology, including ophthalmology, cardiology, dermatology, inflammation, bone disease and women`s health. Additionally, we will expand our in-house development of new chemical entities based on 2ME2- related structures -- that we expect to result in steroidal and non-steroidal analogs -- as we increase our knowledgebase of 2ME2`s mechanisms."

In the first study presented at AACR, investigators concluded that at the molecular level Panzem(R) inhibits microtubules and HIF (hypoxia inducible factor 1 alpha) without associated toxicity. While microtubule targeting agents are a common class of chemotherapeutic agents that include such drugs as paclitaxel and vincristine, their use has been associated with considerable side effects. Microtubules are the scaffold of cells that actively participate in cell division. HIF is a factor that is over-expressed in more than 70% of human cancers and their metastases, including breast, prostate, brain, lung and head and neck cancers and thus, it is an attractive therapeutic target. The complete study was recently published in Cancer Cell.

In the second preclinical investigation, data showed that Panzem(R) inhibited tumor growth in a very relevant animal model that resembles the development of breast cancer in humans. Further, no toxicity was evidenced. These preclinical findings are consistent with EntreMed`s clinical data where Panzem(R), administered in capsule form, has exhibited an excellent safety profile and, when given in combination with Taxotore(R) in a Phase I clinical study, has produced one complete and two partial tumor responses in breast cancer patients.

Resistant cell line data produced from a third Panzem(R) preclinical study presented at AACR will be instrumental to EntreMed scientists for the elucidation of the mechanisms of actions and selection of lead drug candidates from new chemical entities based on 2ME2-related structures.

EntreMed Vice President for Discovery Research, Dr. Victor S. Pribluda, and EntreMed Director for Cell Biology, Dr. Theresa LaVallee, co-authored the three Panzem(R) studies presented at the AACR Annual Meeting as outlined below. The abstracts are available on the EntreMed website at http://entremed.com/corporate/events/AACR2003.cfm.


* "2ME2 Inhibits Angiogenesis and Tumor Growth by Abrogating HIF
Activity Following Microtubule Disruption." Daniel Escuin and
Paraskevi Giannakakou, Emory University.
* "2-Methoxyestradiol Inhibits Estrogen-Receptor Negative Mammary Tumor
Growth in the C3(1)/SV40 Transgenic Mouse Model. Induction of
Apoptosis Through Caspase-3 Activation and Death Receptor-5 (DR5)
Up-Regulation." Alfonso Calvo and Jeffrey E. Green, National Cancer
Institute.
* "Mechanisms of Resistance to 2-methoxyestradiol in MDA-MB-435 Cancer
Cell Line;" Yesim Gokmen-Polar and George W. Sledge, Indiana
University School of Medicine.


About Panzem(R)

Panzem(R) [2-methoxyestradiol (2ME2)] is a naturally occurring metabolite of endogenous estrogens. Its versatile properties and mechanisms of actions allow a wide range of potential formulations for drug delivery to treat numerous indications. In Phase I and Phase II oncology trials, orally administered Panzem(R) has demonstrated anticancer activity in patients with various types of solid tumors, including breast and prostate, as well as multiple myeloma, a blood cancer. Clinical investigators reported patients have shown tumor response, stable disease and/or clinical benefit; one complete and two partial tumor responses were reported in breast cancer patients receiving Panzem(R) in combination with Taxotere(R) and a partial response was reported in an ovarian cancer patient receiving Panzem(R) alone. Panzem(R) was well tolerated by all patients. Results in preclinical models with ocular implants of Panzem(R) have demonstrated that it may inhibit neovascularization of age-related macular degeneration (ARMD). Allergan and EntreMed are developing the localized use of Panzem(R) for the treatment ARMD and other diseases of the eye.

[Guru-Schreck]

4.95 vorbörslich

[schnirchel]

Kennt ihr das Gefühl, wenn man beim Roulette eine Strähne hat?
Es kribbelt mir im Bauch! Irgendwas wird sich in Kürze ereignen. Schaut mal auf die Nasdac!

[meislo]

Researcher: Starving Blood Supply to Tumors Shows Promise
Monday July 14, 3:23 pm ET
By Otesa Middleton


WASHINGTON -- Researchers are finding new pieces to the cancer-treatment puzzle that don`t go so far as to claim a cure, but offer insight into how to stop the growth and spread of tumors.
A key research area known as antiangiogenesis, which focuses on cutting off the blood supply to tumors, has experienced recent success in humans after some three decades of laboratory investigation, said Dr. Judah Folkman.

ADVERTISEMENT


Dr. Folkman, of the Children`s Hospital and Harvard Medical School in Boston, is often credited with being an antiangiogenesis pioneer. The success has prompted further investigation into new combinations and approaches to attacking different cancers, which Dr. Folkman said he hopes will lead to treating cancer like a long-term manageable disease.

Antiangiogenesis research started in earnest in the 1970s as scientists targeted compounds that helped tumors grow the blood vessels on which they fed.

"In 1972, there were three papers published on antiangiogenesis," Dr. Folkman said Monday at the American Association for Cancer Research. "Two were from my lab and one was criticizing them."

Now, he said, this area of research is burgeoning with ideas, studies and promising results.

"Today there are 45 papers per week on antiangiogenesis in cancer, eye disease, gynecological disease and skin disease," Dr. Folkman said.

Dr. Folkman is known for his lab`s discovery of the experimental product endostatin, which is being developed by EntreMed Inc. (NasdaqNM:ENMD - News) .

The endostatin story made big news five years ago and was heralded as a possible cancer cure because the investigational compound eliminated tumors in mice. Since then the drug has stalled in development; however, other drugs that work on a similar premise have shown encouraging results in humans.

"The hardest part of any laboratory work is the translation from the clinic to the patient," Dr. Folkman said.

As new treatments offer fewer side effects and work on patients who haven`t responded to other drugs, Dr. Folkman said, doctors move closer to their goal.

"The question is, can we convert cancer into a chronic-management disease like heart disease or diabetes?" he said.

Studies are under way that look at antiangiogenesis drugs in combination with standard, older treatments. There is a steep learning curve for researchers and ultimately health-care providers to figure out how to add antiangiogenesis products to chemotherapies, radiotherapies and immunotherapies that work on the immune system, Dr. Folkman said



gruss meislo

[meislo]

Der Entwickler von Krebsmedikamenten EntreMed meldet für das zweite Quartal einen Verlust von $5.3 Millionen oder 19 Cents je Aktie nach $11.3 Millionen oder 51 Cents je Aktie Verlust im Vorjahr. Der Umsatz lag bei $286,000 nach $309,000 im Vorjahr. EntreMed konnte den Verlust im abgelaufenen Quartal verringern, da neues Kapital aufgenommen und der Erlös zur Abtragung von Krediten verwendet wurde.


gruss meislo

[Boersi]

Aufwärtstrend noch intakt, langsam wird´s wieder spannend:

[Boersi]

Nachkaufchance

[globalguru]

wenn nicht signifikantes passiert, geht es bis auf 2€ runter. Dann kann man zuschlagen.

gruß

[meislo]

Entrmed bekommt Popoklatsche

Aktuell bei 2,92 Dollar und der Verkaufsdruck nimmt nicht ab dagegen ist cris mit + 14 % ein richtiger Highflyer !



gruss meislo

[globalguru]

Vorsicht ist die Mutter der Porzellankiste. Zum Glück hab ich diesmal gewartet. Irgend etwas ist da im Busch. Ich tippe mal auf unbefriedigende Testergebnisse, welche durch den Buschfunk bis zur Fachpresse gelangt sind. Wenn es so ist, oder vielleicht noch eine KE kommt, geht es noch bis 1,5€ runter.

gruß

[jog_]

Absturz und kein Ende. Hoffentlich hast Du nicht Recht.
Das kann man schon nicht mehr mit "volatilen Augen" sehen.
MfG Jog

[tandill]

Wahrscheinlich nur Panikverkäufe derjenigen, die etwas höher eingestiegen sind. Hat sowieso am Freitag noch gedreht. ENMD ist eine Hopp oder Top Aktie. Bei Top sehen wir neue AT- Höchststände.
mfg

[Tradershark]

Vermutlich wurden auch einige SL ausgelöst!

Die frage ist, wie weit es runter geht, dann gibts
gute Nachkaufchancen!

mfg

Sharky

[Tradershark]

Wann kommen eigentlich die Zahlen?

mfg

Sharky

[schnirchel]

Was läuft da bloß für ein besch..... Spiel ab????

Niedrigste Order, wahrscheinlich unlimitiert. Wer versucht da wen zu locken?

[jog_]

...nicht nur besch... Spiel, - besch... Aktie, Risiko gross, Aufwärts geht´s selten.
Da laufen viele andere richtig gut.

[globalguru]

ENMD
EntreMed, Inc. Nasdaq-NM


Back to Headlines



EntreMed Announces Licensing Deal With Oxford BioMedica

ROCKVILLE, Md., Sep 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- EntreMed, Inc. (Nasdaq: ENMD) today announced the execution of an agreement granting Oxford BioMedica plc (London: OXB) exclusive worldwide rights to develop the localized delivery of two gene targets from EntreMed as a possible treatment for the loss of vision.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Under the terms of the agreement, Oxford BioMedica receives exclusive worldwide rights to use EntreMed`s endostatin and angiostatin genes in the development of locally delivered gene therapy for ophthalmologic applications. Oxford BioMedica plans to utilize EntreMed`s genes in its proprietary therapeutic RetinoStat(TM) program for the treatment of age-related macular degeneration and diabetic retinopathy. In return, EntreMed receives an initial cash payment and Oxford BioMedica common stock. Additionally, EntreMed may collect up to $10 million on the achievement of regulatory and clinical milestones. The Company may receive royalties on future worldwide sales of products resulting from the agreement. EntreMed retains rights to gene therapy applications outside of localized delivery to the eye. EntreMed also retains the rights to the endostatin and angiostatin proteins and is actively pursuing alternative commercialization of these two clinical drug candidates.

Neil Campbell, EntreMed President and Chief Operating Officer, commented, "Given Oxford BioMedica`s gene therapy expertise, we are pleased that we can continue the commercialization of a gene-based endostatin and angiostatin treatment for vision loss. We are also exploring possible relationships with Oxford BioMedica in the areas of hypoxia and hypoxia-induced diseases, such as cancer, anemia and cardiovascular disease." Mr. Campbell continued, "Today`s announcement is the first of several activities EntreMed has been exploring to continue the commercial development of endostatin and angiostatin and further demonstrates EntreMed`s commitment to finalize our stated realignment that will allow the Company to focus solely on its small molecule programs."

Oxford BioMedica`s RetinoStat(TM) is a LentiVector gene delivery system expressing an angiostatic gene under the control of its proprietary hypoxia response element gene switch. RetinoStat(TM) is currently in preclinical development.

[globalguru]

gut möglich das heute nach der Konf. die Post abgeht.

gruß

ROCKVILLE, Md., Sept. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. a biopharmaceutical company focusing on the research and product development of small molecules, today announced that Neil Campbell, EntreMed President and Chief Operating Officer, will speak at the ThinkEquity Partners Growth Conference in San Francisco at the Omni Hotel on Wednesday, September 17, 2003, at 3:00 pm Pacific Time. Mr. Campbell will present an overview of the Company and discuss recent activities.

(Logo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

A live webcast of the presentation will be available online at http://www.entremed.com/. To listen to the webcast, please log onto EntreMed``s website at least ten minutes prior to the start of the event and follow the instructions. The webcast will be archived on the Company website.

[globalguru]

+16% fast auf Tageshöchststand!!!
Weiß jemand mehr, was gestern auf der Konf. bekanntgegeben wurde?

gruß

[ollihat]

Hat vielleicht mal einer einen plausiblen Kommentar für die 19% Kurssteigerung heute?

[Boersi]

zu 63#

Biotechrally...

[schnirchel]

Was soll der Quark?
Schaut euch doch mal die Umsätze an?
Lächerlich da von einem Hype zu sprechen!
Träumer.

[tandill]

Ist ja schon wieder alles weg.
mfg

[luto9]

ROCKVILLE, Md., Sep 30, 2003 /PRNewswire-FirstCall via COMTEX/ --
EntreMed, Inc. (Nasdaq: ENMD), a biopharmaceutical company focusing on the research and product development of small molecules, today announced the Company has selected the final formulations of Panzem(R), EntreMed`s lead drug candidate currently in Phase II oncology trials. EntreMed expects to transition the reformulated Panzem(R) into new clinical trials in early 2004. These new formulations, all orally administered, are designed to increase the amount of Panzem(R) that circulates in the patient`s bloodstream by increasing absorption of the drug candidate.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed President and Chief Operating Officer Neil Campbell commented, `These new Panzem(R) formulations build upon the positive clinical profile of the current Panzem(R) that includes tumor regression, stable disease and lack of toxicity. Based on preclinical data, the Panzem(R) formulations we are finalizing have exceeded our requirements for enhancement of absorption and bioavailablity. In order to maximize our options, we are working closely with three companies that have the technical capability and manufacturing capacity to supply us with GMP clinical trial material.`Campbell continued, `The Panzem(R) clinical development program remains on track and we expect to transition the improved Panzem(R) formulation into new clinical trials in early 2004.`

The new Panzem(R) formulations result in circulating levels more than ten fold higher in preclinical animal models when compared to the existing formulation. Further, preliminary toxicity studies indicate that the newly formulated Panzem(R) has a strong safety profile, similar to the current clinical formulation. The new Panzem(R) formulations have been prepared using existing supplies of Panzem(R) bulk material purchased in May 2003. This bulk material is being used to prepare GMP material for clinical trials beginning in the first quarter of 2004.

About Panzem(R)

Panzem(R) [2-methoxyestradiol (2ME2)] is a naturally occurring metabolite of endogenous estrogen. Its versatile properties allow a wide range of potential formulations for drug delivery to treat numerous indications. In Phase I and Phase II oncology trials, orally administered Panzem(R) has demonstrated anticancer activity in patients .......

[globalguru]

#30 w.z.b.w

EntreMed Raises Over $22 Million in Private Equity Transaction

ROCKVILLE, Md., Nov 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- EntreMed, Inc. (Nasdaq: ENMD), a biopharmaceutical company focusing on the research and development of small molecule therapeutics, today announced it has raised approximately $22.3 million in gross proceeds in an issuance of common stock and warrants to certain independent institutional investors. Proceeds from the transaction will be used for the clinical development of reformulated Panzem(R), continued preclinical and discovery efforts and additional working capital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed President and Chief Operating Officer Neil Campbell commented, "The Company remains committed to prudent resource management. Today`s transaction was an opportunity for EntreMed to secure additional funds to support our current and planned operations. These additional funds, together with our cash on-hand, will support our operations well into 2005." The Company plans to provide its third quarter financial results for the period ending September 30, 2003, on Thursday, November 6, 2003.

The Company sold a total of approximately 5.25 million shares at $4.25 per share. The total number of five-year warrants was equivalent to 15% of the total number of shares of common stock issued, with an exercise price of $5.00 per share. EntreMed has agreed to file a registration statement with the SEC within 30 days to permit resales of the common stock by the investors. Rodman & Renshaw, Inc. acted as the placement agent for this transaction.

[jog_]

Wie weit fällt denn dieses Sch...papier noch.
(an einem schwarzen Feitag gekauft und so läuft´s auch).

bei weiterhin schlechter Marktsituation rauscht die sicher bis unter die 200-Tagelinie.
MfG jog_

[meislo]

Press Release Source: EntreMed, Inc.


EntreMed`s Novel Small Molecule Inhibits Tumor Growth in Preclinical Models
Sunday December 7, 12:15 pm ET
PAR-2 Inhibitor to Strengthen Oncology Pipeline


ROCKVILLE, Md., Dec. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a biopharmaceutical company focusing on the research and development of small molecule therapeutics, today presented data on the Company`s discovery that the proteinase activated receptor-2 (PAR-2), associated with inflammation, also plays a critical role in tumor growth and formation of new blood vessels in preclinical models. In addition, EntreMed scientists have designed the first compounds known to specifically inhibit PAR-2. As part of its peptidomimetic approach to small molecules, EntreMed scientists designed a peptide and then a more potent small molecule peptidomimetic to block the signaling of PAR-2. In vivo studies demonstrate that this small molecule mimetic is significantly more potent than the peptide. The Company plans to further evaluate these compounds in a variety of cancer and inflammation disease models.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
President and Chief Operating Officer Neil Campbell said, "EntreMed scientists have made two significant discoveries that further our scientific and business strategies. First, we have discovered that PAR-2 is a previously unrecognized factor in tumor growth and angiogenesis. And second, we have created novel compounds -- peptides and small molecule mimetics -- that inhibit tumor growth by blocking PAR-2. This work reflects not only the strength of our discovery and preclinical capabilities, but also identifies PAR-2 as a target for potential therapeutic applications in oncology and diseases associated with inflammation and angiogenesis." Campbell continued, "The PAR-2 intellectual property belongs exclusively to EntreMed, similar to many compounds in our pipeline that have been discovered and currently under development in-house."

Specifically, EntreMed scientists developed the first peptide PAR-2 antagonist, p520. Using the p520 structure as a template, they designed peptidomimetic antagonists, including 547m that demonstrates a ten-fold increase in antitumor activity when compared to the parental p520 peptide.

The PAR-2 data were presented in San Diego, California during the American Society of Hematology Annual Meeting. The poster, entitled "Novel Antagonists of PAR-2: Inhibition of Tumor Growth, Angiogenesis and Inflammation" was presented by Todd Hembrough, PhD, EntreMed Senior Research Scientist, and is available at www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage biopharmaceutical company developing therapeutics that simultaneously target the biological pathways of angiogenesis (abnormal blood vessel growth) inflammation, coagulation and/or apoptosis (programmed cell death) -- pathways associated with over 80 diseases such as cancer, blindness and atherosclerosis. The Company`s clinical drug candidates, led by the small molecule Panzem®, have shown a strong safety profile with neither toxicity nor clinically significant side effects reported to date. Further, doctors have reported tumor regression and disease stabilization in some clinical patients that have received EntreMed drug candidates. The Company also has a rich pipeline of small molecule compounds in preclinical development, consisting primarily of new chemical entities based on 2-methoxyestradiol-related structures (steroidal and non-steroidal analogs) and chemically-derived small molecules from peptides - peptidomimetics. For further information, visit EntreMed`s web site at www.entremed.com.

[kurttilly]

Hallo alle Entremed-Interessierten!

Kann jemand sagen, warum Entremed heute so abschmiert?

mfg

kurttilly

[jog_]

der abwärtstrend ist wohl eindeutig. hält die 200-tagelinie, vermute ich, könnte es kurzfristig nach oben gehen. (W-formation).

sollte sie nicht halten, dann mahlzeit!!

grüsse jog_

[jog_]

...war wohl nichts.
diese aktie ist eine einzige schlappe.

[jog_]

in den letzten tagen haben institutionelle zu ca. 3% verkauft!

hat jemand eine ahnung, was bei enmd läuft?

mfg jog_

[tandill]

http://www.spiegel.de/wissenschaft/mensch/0,1518,279514,00.h…

Noch besteht Hoffnung...

mfg

[meislo]

EntreMed`s Novel Peptide Demonstrates Tumor Inhibition in Preclinical Models
Thursday January 22, 10:00 am ET


ROCKVILLE, Md., Jan. 22 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a biopharmaceutical company focusing on the research and development of small molecule therapeutics, today announced that it identified a peptide fragment of Tissue Factor Pathway Inhibitor (TFPI), a naturally occurring anti-coagulant protein, that blocks tumor growth and angiogenesis in in vivo models. While this peptide inhibits metastatic tumor and blood vessel growth, it does not appear to affect normal blood clotting -- a hurdle long associated with the development of TFPI and other coagulation inhibitors for oncology. EntreMed scientists also identified the TFPI peptide`s mechanism of action. These discoveries support the continued development of new oncology drug candidates based on the TFPI peptide fragment.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Neil Campbell, EntreMed President and Chief Operating Officer, stated, "Having successfully isolated a small peptide containing TFPI`s anti-tumor and anti-angiogenesis activity, without affecting coagulation, our R&D team is using the peptide as a template to design small molecules with similar, but improved, properties. The resulting compounds may be less costly and more predictable to develop as therapeutics with possible treatment applications for oncology, as well as inflammatory and cardiovascular diseases." Campbell commented, "Today`s data continue to demonstrate our strong in-house discovery capabilities and the potential of our product pipeline."

The paper entitled "Identification and Characterization of a Very Low Density Lipoprotein Receptor Binding Peptide from Tissue Factor Pathway Inhibitor that has Anti-tumor and Anti-angiogenic Activity" will be available later today online at "Blood," The Journal of the American Society of Hematology (www.bloodjournal.org). The EntreMed team responsible for this work was led by Todd Hembrough, PhD, EntreMed Senior Research Scientist; co- authors also include scientists from the American Red Cross, Holland Laboratory.

About EntreMed

EntreMed, Inc. is a clinical-stage biopharmaceutical company developing therapeutics that simultaneously target the biological pathways of angiogenesis (abnormal blood vessel growth) inflammation, coagulation and/or apoptosis (programmed cell death) -- pathways associated with over 80 diseases such as cancer, blindness and atherosclerosis. The Company`s clinical drug candidates, led by the small molecule Panzem®, have shown a strong safety profile with neither toxicity nor clinically significant side effects reported to date. Further, doctors have reported tumor regression and disease stabilization in some clinical patients that have received EntreMed drug candidates. The Company also has a rich pipeline of small molecule compounds in preclinical development, consisting primarily of new chemical entities based on 2-methoxyestradiol-related structures (steroidal and non-steroidal analogs) and chemically-derived small molecules from peptides -- peptidomimetics. For further information, visit EntreMed`s web site at

[globalguru]

jetzt wird es kritisch. Entremed verscherbelt das Tafelsilber. Die sind zwar noch mit 20% an Lizenzeinnahmen beteiligt, aber die große Phantasie ist raus.

gruß

EntreMed Transfers Rights to Endostatin & Angiostatin



ROCKVILLE, Md., Feb. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc.(NASDAQ-NMS:ENMD) (Nasdaq: ENMD), a biopharmaceutical company focusing on the research and development of small molecule therapeutics, today announced the transfer of all rights for its protein-based drug candidate programs, endostatin and angiostatin, in an agreement with Children`s Medical Center Corporation (CMCC) in Boston and Alchemgen Therapeutics, Inc. Pursuant to the agreement, CMCC and Alchemgen continue the development of endostatin and angiostatin and bear all expenses associated with such programs, including costs that EntreMed may incur in transferring these compounds. In exchange for these programs, EntreMed receives upfront and future cash and royalty payments. Clinical patients currently receiving endostatin and angiostatin continue to be treated.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

In 2003, EntreMed made a strategic decision to concentrate the Company`s research and development efforts on its small molecule oncology program. The Company`s activities are now directed to its Phase II clinical program and advanced preclinical pipeline.

Neil Campbell, EntreMed President and Chief Operating Officer, commented, "This agreement with Children`s and Alchemgen ensures the continued commercial development of endostatin and angiostatin, while we focus our financial and scientific resources on our promising product candidate pipeline. As we enter 2004, we have significantly strengthened our financial position."

Under the terms of the three-party agreement, the Houston-based, privately-held company Alchemgen receives exclusive rights to market endostatin and angiostatin in Asia. CMCC holds the license for the rest of the world. EntreMed receives 20% of all future proceeds (e.g. upfront, milestone and royalty payments) resulting from any subsequent CMCC license outside of Asia.

[tandill]

Würde ich nicht so negativ sehen. Im Yahoo-Board gibt es darüber eine heftige Debatte. 20% wären beträchtlich, wenn dem so wäre. Außerdem gibt es Cash. ENMD ist einfach zu klein um das alleine zu schaffen. Ich glaube, der Ausverkauf wurde Freitag gestoppt.

mfg

[globalguru]

@tandill

wie siehst Du dann diese Meldung?
Reinverlust 20,5Mill§ in 2003 bei nur noch 36,8Mill$ cash.

EntreMed Reports Fourth Quarter and Year-End 2003 Results



ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- EntreMed, Inc.(NASDAQ-NMS:ENMD) (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2003.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the fourth quarter ended December 31, 2003 were approximately $518,000 versus $462,000 for the comparable period in 2002. The Company reported a net loss of approximately ($6.2 million), or ($0.18) per share for the three months ended December 31, 2003. This compares with a net loss of approximately ($1.5 million), or ($0.07) per share for the fourth quarter 2002, when EntreMed recognized a $2.9 million gain on the sale of an asset and recorded a $2.1 million gain on the discharge of liabilities.

For the year ended December 31, 2003, the Company reported revenues of approximately $1.6 million versus $1.8 million for 2002. Net loss for fiscal year 2003 was ($20.5 million) or ($0.68) per share, versus ($39.0 million), or ($1.78) per share, for fiscal year 2002. As of December 31, 2003, the Company had cash and short-term investments of approximately $36.8 million.

Neil Campbell, EntreMed President and Chief Operating Officer, commented, "With our transition complete, in 2004 we are directing our attention to maintaining prudent management of our resources and to the further advancement of our clinical and preclinical programs. We continue to make progress on bringing the new formulation of Panzem(R) into the clinic. In preparation, we purchased bulk Panzem(R) materials during the fourth quarter, which increased R&D costs by approximately $1.5 million and our loss by $0.05 per share."

EntreMed will hold a conference call today at 11:00 a.m. EST to present its fourth quarter and year-end results. A live webcast of the conference call will be available online at www.entremed.com; please log onto EntreMed`s website at least ten minutes prior to the start of the event and follow the instructions.



gruß

[tandill]

Ohne Frage, die Lage ist kritsch. Allerdings ist ein Kostenblock (Endostatin und Angiostatin) abgegeben worden.
Und das ist gut so. Meiner Ansicht nach ist Panzem die bessere Alternative. Der Kursverlauf gestern sprach Bände. Erst abtauchen und dann wieder auftauchen. Wahrscheinlich nach der Konferenz. Panzem soll dieses (Halb)jahr in die klinische Erprobung kommen. Hier steckt noch viel Hoffnung und Phantasie drin.

Wir werden sehen, aber die Konkurenz ist groß

mfg

[kurttilly]

Hi zusammen!

Hat denn noch niemand hier gemerkt, wie Entremed gestern in USA abging?

Heute schon über 20% !

kurttilly

[Tradershark]

Alles okay, nur keiner weis warum??????????????
Es gibt keine News, einfach nichts!!!

Was ist da los??

mfg

Sharky

[meislo]

FDA Approves Genentech`s Avastin for Colorectal Cancer
Thursday February 26, 3:57 pm ET
By Otesa Middleton


WASHINGTON -- Genentech Inc. (NYSENA - News) won Food and Drug Administration (News - Websites) approval for its new colon-cancer drug Avastin, making it the first such drug that starves tumors by preventing new blood vessels from forming.
ADVERTISEMENT


Avastin`s approval represents the first major success of a so-called angiogenesis inhibitor, a class of experimental products that started a buzz six years ago when EntreMed Inc. (NasdaqNM:ENMD - News) claimed it cured cancer in mice by cutting off the blood vessels that fed tumors oxygen and nutrients.

The news sent biotech stocks soaring, but Genentech`s drug is the first to pass FDA muster.

In a move out of character for the agency, Avastin won approval as a first option for patients with spreading colon cancer. Typically when a new cancer treatment receives FDA approval, the agency labels it for second-line use after a long-proven regimen fails. After time on the market, drug makers usually then ask the FDA to approve it for more widespread, and earlier, use.

In studies, patients on Avastin lived about five months longer when given in combination with the commonly used Saltz regimen, which includes the drugs 5-FU, leucovorin and Pfizer Inc. (NYSE:PFE - News)`s Camptosar, which is often called CPT-11 or irinotecan.

Made from both human and mouse components, the intravenous drug is the first proven medicine to stunt tumor growth and significantly extend patients` lives.

"The approval of Avastin is the result of many years of research and development exploring a promising new approach to fighting cancer," said FDA Commissioner Dr. Mark B. McClellan. The agency plans a 4 p.m. EST press conference call on the Avastin approval.

Cancer in the colon or rectum is the No. 2 cause of cancer deaths in the U.S. behind lung cancer.

[globalguru]

Der Chef verlässt das sinkende Schiff. Eigentlich traurig um diesen so hoffnungsvollen Wert. EinGlück das ich schon vorher raus bin.

gruß

EntreMed President & COO to Step Down



ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ -- EntreMed, Inc.(NASDAQ-NMS:ENMD) (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer, today announced that Neil Campbell will step down as EntreMed(NASDAQ-NMS:ENMD) President & Chief Operating Officer effective May 30, 2004. EntreMed`s(NASDAQ-NMS:ENMD) Board of Directors has been engaged in a search for a Chief Executive Officer to lead the Company`s day-to-day operations and expects to conclude the search in the near future. Mr. Campbell will continue his relationship with the Company to facilitate a smooth transition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

EntreMed(NASDAQ-NMS:ENMD) Chairman of the Board, Michael Tarnow, commented, "Neil has played a key role in positioning EntreMed(NASDAQ-NMS:ENMD) as a viable company with a solid drug candidate pipeline. Under Neil`s leadership, EntreMed(NASDAQ-NMS:ENMD) returned to stable financial ground, completed the corporate transition to a small molecule- focused company and redirected the R&D efforts, including our clinical program. The Board, along with the entire EntreMed(NASDAQ-NMS:ENMD) team, thanks Neil for his dedication, leadership and contributions to the Company."

Neil Campbell stated, "EntreMed`s(NASDAQ-NMS:ENMD) transition has been achieved successfully and I am proud of the Company`s progress. I intend to explore other opportunities that would be unavailable to me, if I remained with EntreMed(NASDAQ-NMS:ENMD) ."

[NOBODY_III]

Nach einem Kurssturz, wahrscheinlich aufgrund der Qu.II-Zahlen, konnte Entremed gestern wieder um 14,7 % auf 1,48 USD anziehen.

Nachrichten dazu waren nirgends zu finden.

Vielleicht hat jemand entdeckt, daß Entremed auch etwas mit Nanotechnologie zu tun hat.

Zitat aus der folgenden Meldung:

EntreMed legt durch Kooperation mit Elan über 13 Prozent zu 1 Redaktion WO [W:O] 13.07.04 20:50:32

Das amerikanische Biotechnologieunternehmen EntreMed Inc. hat am Dienstag bekannt gegeben, dass das irische Pharmanunternehmen Elan Corp. die von EntreMed entwickelte NanoCrystal-Technologie zur Entwicklung eines neuen Krebspräparats verwendet.

[NOBODY_III]

Entremed zieht heute um 6,8 % auf 1,58 USD an.
Tageshoch 1,65 USD. (gestern + 14,7 % auf 1,48 USD)

Handelt es sich dabei um eine technische Reaktion auf den vorausgegangenen Absturz?
Oder weiß jemand mehr?

[NOBODY_III]

Entremed konnte inzwischen weiter anziehen bis auf rund 1,80 USD.

Hier im Forum haben sich die Entremed-Fans unterdessen wohl verabschiedet. Oder?

Der zur Zeit stabile Kurs hängt wahrscheinlich mit folgender Meldung zusammen:

29.09.2004 16:06:
EntreMed Presents Additional Panzem(R) (2ME2) Preclinical Data at EORTC-NCI-AACR Symposium

ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- EntreMed (Nachrichten), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer, today announced further preclinical data on Panzem(R) (2ME2 or 2-methoxyestradiol) demonstrating its anti-cancer activity and associated plasma drug levels in several animal tumor models. These findings, together with previous experiments, indicate that maintaining increased levels of 2ME2 for longer time periods improves anti- tumor activity. These data were presented today at the 16th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," in Geneva, Switzerland.

The new 2ME2 formulation, called Panzem NCD(R), will enter future clinical trials as an oral suspension given every six hours. Using a multiple daily dosing approach, EntreMed is seeking to sustain plasma levels and concentrations of 2ME2 at higher levels than those reached with the previous 2ME2 capsule formulation. Further, the new liquid formulation and dosing schedule of Panzem NCD(R) is intended to maintain plasma levels within the therapeutic range where anti-cancer activity has been demonstrated in animal models. Elan Drug Delivery, Inc. is manufacturing Panzem NCD(R) for EntreMed using its proprietary NanoCrystal(R) technology.

Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer, said, "The data presented today have, in part, played an important role in developing the clinical trial protocol for Panzem NCD(R), our lead drug candidate. We look forward to moving this orally-dosed drug candidate into patient trials in early 2005."

For detailed information regarding the poster, "Maximizing the anti-tumor and anti-proliferative effects of 2ME2 by maintaining levels above a threshold concentration for a defined period of time" by Anthony M. Treston, Glenn Swartz, Beth Chen, Art Hanson, Wanda Smith, Kirk Volker, Stacy Plum, Carolyn Sidor, William E. Fogler, and Udo Klein, please refer to http://www.entremed.com/.

About Panzem NCD(R)

Panzem NCD(R), EntreMed`s lead clinical candidate, is developed from the molecule, 2-methoxyestradiol (2ME2). Panzem works through multiple mechanisms of action (MOA), including inhibiting angiogenesis, disrupting microtubule formation, down regulating hypoxia inducible factor one-alpha (HIF-1a), and inducing apoptosis (cell death). The 2ME2 mechanisms that are particularly relevant to the treatment of cancer involve inhibiting endothelial cell growth (anti-angiogenic activity) and killing tumor cells directly (pro-apoptotic activity). As a further result of its multiple MOA, 2ME2 may have potential therapeutic applications in other non-oncology diseases.

Although it is a naturally occurring estrogen metabolite, 2ME2 has little estrogenic activity because it binds poorly to known estrogen receptors. The activity of 2ME2 has been demonstrated in cell lines that are resistant to various chemotherapy agents including taxanes (microtubule stabilizing agents); etoposide, adriamycin and methotrexate (DNA synthesis interfering agents); and tamoxifen (anti-estrogen agent).

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer. Panzem(R) (2-Methoxyestradiol or 2ME2), the Company`s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for indications outside of oncology. EntreMed`s goal is to develop and commercialize new compounds based on the Company`s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases. The Company`s expertise has also led to the discovery of new molecules, including analogs of 2ME2, and inhibitors of fibroblast growth factor-2 (FGF-2), tissue factor pathway (TFP) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering.

Forward Looking Statements

This release contains, and other statements that EntreMed may make may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are typically identified by words or phrases such as "believe," "feel," "expect," "anticipate," "intend," "outlook," "estimate," "target," "assume," "goal," "objective," "plan," "remain," "seek," "trend," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "might," "can," "may," or similar expressions. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and EntreMed assumes no duty to update forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in EntreMed`s Securities and Exchange Commission filings under "Risk Factors," including risks relating to EntreMed`s need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem(R); dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company`s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

Quelle: PR Newswire (USA)

[NOBODY_III]

Anscheinend hatte der stabile Kurs etwas zu bedeuten.

Heute explodiert Entremed und zwar nachrichtenlos.

Börse Symbol Währ. Vortag akt.Kurs Diff. % Handelsvol. gehand. St. Kurszeit
Nasdaq ENMD USD 1,82 2,18 + 0,360 + 19,78 % 1,39 Mio. 698.482 11. Okt 17:52
Frankfurt ENM EUR 1,40 1,80 + 0,400 + 28,57 % 12.313 7.335 11. Okt 17:23
München ENM EUR 1,44 1,69 + 0,250 + 17,36 % 3.708 2.200 11. Okt 17:16
Berlin ENM EUR 1,38 1,41 + 0,030 + 2,17 % 0 0 11. Okt 09:07
Stuttgart ENM EUR 1,40 1,51 + 0,110 + 7,86 % 0 0 11. Okt 15:34

Weiß jemand näheres zu den Hintergründen?

[NOBODY_III]

Nach wie vor keine Nachrichten.

Nur auf der HP war folgender Hinweis zu finden:

Live Webcast
EntreMed, Inc. at BIO Emerging Company Investor Forum
October 15, 2004, 11:10 AM PT

Vielleicht hat es deswegen in USA eine Kaufempehlung gegeben.

Habe bei 1,80 € verkauft. 28,57 % Tagesgewinn gibt es auch nicht alle Tage.

[NOBODY_III]

ENTREMED (NasdaqNM: ENMD)
Delayed quote data by Reuters

After Hours (RTM/ECN): 2.21 0.04 (1.78%)

Last Trade: 2.25
Trade Time: 3:59PM ET
Change: 0.43 (23.63%)
Prev Close: 1.82
Open: 1.68
Bid: 2.07 x 1000
Ask: 2.24 x 100
1y Target Est: 8.00

Day`s Range: 1.47 - 2.41
52wk Range: 1.24 - 5.928
Volume: 1,938,364
Avg Vol (3m): 169,954
Market Cap: 83.37M
P/E (ttm): N/A
EPS (ttm): -0.593
Div & Yield: N/A (N/A)

Leider gibt es immer noch keine News zu dieser Kursexplosion. Oder kann jemand helfen?

Irgend etwas muß im Busch sein.

Folgende Punkte fallen auf:

Die Aktie fällt vom Vortagesschlußkurs von 1,82 auf 1,47 USD zurück, um dann in der Spitze bis auf 2,41 USD anzusteigen. Die Tagesbandbreite beträgt bemerkenswerte 63,9 %.

Das heutige Handelsvolumen von 1.938.364 ist im Schnitt
8 x so hoch wie an normalen Tagen:



Date Open High Low Close Volume Adj Close*
8-Oct-04 1.82 1.82 1.77 1.82 211,200 1.82
7-Oct-04 1.70 1.84 1.70 1.78 221,400 1.78
6-Oct-04 1.74 1.82 1.71 1.76 210,500 1.76
5-Oct-04 1.80 1.85 1.79 1.82 250,500 1.82
4-Oct-04 1.78 1.80 1.74 1.78 215,800 1.78
1-Oct-04 1.88 1.90 1.65 1.75 204,200 1.75
30-Sep-04 1.78 1.78 1.70 1.73 149,500 1.73
29-Sep-04 1.63 1.87 1.63 1.71 501,500 1.71
28-Sep-04 1.64 1.72 1.61 1.67 72,500 1.67
27-Sep-04 1.67 1.73 1.58 1.62 106,600 1.62
24-Sep-04 1.70 1.70 1.62 1.63 69,100 1.63
23-Sep-04 1.67 1.75 1.66 1.66 77,300 1.66
22-Sep-04 1.66 1.72 1.60 1.66 88,200 1.66
21-Sep-04 1.72 1.80 1.70 1.75 90,400 1.75
20-Sep-04 1.89 1.89 1.70 1.74 117,300 1.74
17-Sep-04 1.85 1.85 1.75 1.80 112,500 1.80
16-Sep-04 1.77 1.89 1.65 1.81 593,700 1.81
15-Sep-04 1.64 1.68 1.61 1.64 59,000 1.64
14-Sep-04 1.70 1.70 1.60 1.67 98,200 1.67
13-Sep-04 1.43 1.69 1.43 1.68 210,300 1.68
10-Sep-04 1.51 1.51 1.45 1.49 24,400 1.49
9-Sep-04 1.50 1.50 1.45 1.47 49,900 1.47
8-Sep-04 1.53 1.53 1.42 1.45 44,500 1.45
7-Sep-04 1.42 1.52 1.42 1.46 63,200 1.46
3-Sep-04 1.48 1.52 1.48 1.51 43,200 1.51
2-Sep-04 1.46 1.58 1.40 1.52 150,800 1.52
1-Sep-04 1.38 1.45 1.35 1.44 130,700 1.44
31-Aug-04 1.43 1.44 1.37 1.37 152,600 1.37
30-Aug-04 1.48 1.59 1.40 1.42 209,100 1.42
27-Aug-04 1.55 1.60 1.50 1.59 139,500 1.59
26-Aug-04 1.62 1.69 1.57 1.61 66,100 1.61
25-Aug-04 1.70 1.70 1.60 1.63 88,500 1.63
24-Aug-04 1.70 1.71 1.56 1.61 91,500 1.61
23-Aug-04 1.52 1.68 1.52 1.60 131,700 1.60
20-Aug-04 1.57 1.62 1.42 1.56 101,500 1.56
19-Aug-04 1.54 1.65 1.49 1.58 180,900 1.58
18-Aug-04 1.31 1.52 1.29 1.48 226,400 1.48
17-Aug-04 1.30 1.32 1.27 1.29 86,200 1.29
16-Aug-04 1.25 1.37 1.25 1.28 122,600 1.28
13-Aug-04 1.26 1.33 1.26 1.28 70,400 1.28
12-Aug-04 1.31 1.36 1.24 1.28 73,800 1.28
11-Aug-04 1.26 1.37 1.25 1.36 125,500 1.36
10-Aug-04 1.36 1.41 1.25 1.30 195,200 1.30
9-Aug-04 1.43 1.44 1.35 1.40 59,200 1.40
6-Aug-04 1.37 1.46 1.31 1.38 154,900 1.38
5-Aug-04 1.54 1.58 1.37 1.49 236,600 1.49
4-Aug-04 1.70 1.70 1.52 1.55 159,400 1.55
3-Aug-04 1.63 1.81 1.55 1.68 221,900 1.68
2-Aug-04 1.62 1.70 1.56 1.61 112,700 1.61
30-Jul-04 1.72 1.73 1.68 1.72 70,500 1.72
29-Jul-04 1.72 1.75 1.61 1.70 65,600 1.70
28-Jul-04 1.74 1.83 1.65 1.71 80,500 1.71
27-Jul-04 1.60 1.83 1.57 1.74 225,000 1.74
26-Jul-04 1.71 1.88 1.55 1.62 245,700 1.62
23-Jul-04 1.77 1.88 1.70 1.71 81,200 1.71
22-Jul-04 1.81 1.94 1.75 1.84 110,900 1.84
21-Jul-04 1.77 1.93 1.77 1.84 141,900 1.84
20-Jul-04 1.84 1.86 1.74 1.85 88,600 1.85
19-Jul-04 1.87 1.91 1.75 1.76 169,600 1.76
16-Jul-04 1.90 1.97 1.88 1.89 105,100 1.89
15-Jul-04 1.82 1.99 1.82 1.86 277,000 1.86
14-Jul-04 1.98 2.00 1.82 1.82 304,600 1.82
13-Jul-04 1.67 2.21 1.67 1.96 1,291,700 1.96
12-Jul-04 1.73 1.85 1.56 1.68 391,500 1.68
9-Jul-04 1.79 1.84 1.70 1.83 208,700 1.83
8-Jul-04 1.88 1.88 1.76 1.80 186,000 1.80

Sorry, wenn es etwas länger geworden ist. Aber man kann es ja schnell überfliegen.

Lediglich am 13.07.04 fiel es mit 1.291.700 aus der Reihe.
Das war der Tag, an dem die Kooperation mit Elan gemeldet wurde.
An der Übersicht läßt sich aber auch ganz gut erkennen, wie schnell das Handelsvolumen wieder normale Größenordnungen annahm und wie lange sich die Kurse auf dem höheren Niveau halten konnten.

Bin gespannt, was dahinter steckt.

[ollihat]

Eine mögliche Erklärung für den Kursanstieg ist der Artikel "Revolutionary approach hails improved cancer treatment", der im www.drugresearcher.com/news veröffentlicht wurde.

Darin wird über eine Angiogenese Studie berichtet, die während des EORTC-NCI-AACR Symposiums in der Schweiz vorgestellt wurde.Die wohl wichtigste Aussage des leitenden Forschers, Dr. Feron, lautet:
"What this means is that we may have the potential to use drugs to selectively exploit these blood vessels against the tumor instead of, or before, killing them. Exploiting tumor blood vessels instead of destroying them by angiogenic drugs constitutes a paradigm shift in approach to angiogenesis."

Entremed wäre Nutznießer, weil es Lizenzen gibt. Müßte man nochmals genauer recherchieren!

[NOBODY_III]

Danke für den Hinweis!

Kein Wunder, daß die Presse den Kursanstieg bisher nicht kommentiert.
Da muß man ja schon Mediziner sein, um die Tragweite beurteilen zu können.

Aber in USA müßte es den einen oder anderen Börsendienst geben, der den Kauf empfohlen hat.
Ein 8 facher Tagesumsatz kommt ja nicht aus heiterem Himmel
zustande.

Über www.finanznachrichten.de und Yahoo weltweit sind leider noch keine News zu finden.

[NOBODY_III]

Es finden sich leider immer noch keine Nachrichten zu der gestrigen Kursexplosion.

Das einzige, was es gibt, sind neue Kurse aus Amerika.

Dort notiert Entremed nach einem Schlußkurs von 2,25 €
heute mit einem kräftigen Minus:

Tageshoch: 2,15 USD

Tagestief: 2,02 USD

Kurs aktuell: 2,08 USD (- 7,56 %)

[NOBODY_III]

13.10.2004 12:01:
EntreMed to Present at BIO Emerging Company Investor Forum

ROCKVILLE, Md., Oct. 13 /PRNewswire-FirstCall/ -- EntreMed (Nachrichten), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer, today announced that James S. Burns, President and CEO, will present a company overview at the BIO Emerging Company Investor Forum being held this week at the Palace Hotel in San Francisco, California. Mr. Burns` presentation is scheduled for Friday, October 15, 2004 at 11:10 a.m. Pacific Time.

The presentation will be web cast and is available on EntreMed`s web site at http://www.entremed.com/. An archive of the presentation will be available on the Company`s web site approximately one hour after the live presentation.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer. Panzem(R) (2-Methoxyestradiol or 2ME2), the Company`s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for indications outside of oncology. EntreMed`s goal is to develop and commercialize new compounds based on the Company`s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases. The Company`s expertise has also led to the discovery of new molecules, including analogs of 2ME2 and peptides of tissue factor pathway inhibitor (TFPI) and inhibitors of fibroblast growth factor-2 (FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering.

-----------------------------------------------------------------------------------------------------------------------------

Über diese Präsentation informierte ich bereits am 11.10.04 unter # 89

[NOBODY_III]

19.10.2004 12:09:
EntreMed to Present at Rodman & Renshaw Healthcare Conference

ROCKVILLE, Md., Oct. 19 /PRNewswire-FirstCall/ -- EntreMed (Nachrichten), a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer, today announced that James S. Burns, President & CEO, will provide a Company overview at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference being held October 26-28, 2004 at the Waldorf-Astoria in New York. Mr. Burns is scheduled to present on Wednesday, October 27, 2004 from 10:50 am to 11:10 am Eastern Time.

The live presentation will be web cast and available at http://www.entremed.com/. Approximately one hour after the live presentation, an archive will be available on the Company`s web site.

About EntreMed

EntreMed, Inc. is a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer. Panzem(R) (2-Methoxyestradiol or 2ME2), the Company`s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for indications outside of oncology. EntreMed`s goal is to develop and commercialize new compounds based on the Company`s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases. The Company`s expertise has also led to the discovery of new molecules, including analogs of 2ME2, peptides of tissue factor pathway inhibitor (TFPI), and inhibitors of fibroblast growth factor-2 (FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering.

CONTACT: Ginny Dunn, Associate Director Corporate Communications & Investor Relations, of EntreMed, Inc., [phone].

EntreMed, Inc.

[Cyberhexe]

...demonstrated that the vaccine generates anti-angiogenic and anti-tumor activity in the absence of toxicity. In addition, the vaccine had no effects on normal physiology specifically related to wound healing and reproduction in preclinical models.


http://biz.yahoo.com/prnews/041020/dcw015a_1.html

sind auf meiner Beobachtungsliste!

[ollihat]

Anläßlich der Erteilung eines neuen US Patentes veröffentlicht ENMD eine Pressemitteilung, in der nochmals bestätigt wird, daß das dafür entwickelte Serum, genannt ENMD 0996, im Tierversuch sowohl antiangiogenetische Wirkung hatte als auch Tumorwachstum verhindert hat.

Das hört sich gut an!
Aber natürlich ist der Weg noch weit.

[NOBODY_III]

26.10.2004 12:08:
EntreMed and Affymax Announce Collaboration for Novel TFPI Peptides

ROCKVILLE, Md. and PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- EntreMed (Nachrichten), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammation, and Affymax, Inc., a clinical-stage pharmaceutical company developing therapeutics for treatment of anemia and cancer, today announced that they have entered into a research collaboration for the synthesis and development of novel peptides that mimic certain fragments of tissue factor pathway inhibitor (TFPI). TFPI is a naturally occurring anticoagulant protein that inhibits tumor growth and the formation of new blood vessels in preclinical models.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Under the terms of the agreement, EntreMed and Affymax will combine expertise in peptide design and drug development with the goal of identifying lead drug candidates for the treatment of cancer. EntreMed scientists have identified a peptide fragment of TFPI that maintains the protein`s anti- angiogenic and anti-tumor properties without adversely affecting normal blood clotting when tested in animal models. EntreMed`s TFPI peptide represents a positive step forward in overcoming the limitations that have prevented the development of TFPI as a therapeutic agent for oncology.

Affymax is a leader in the discovery and development of novel peptide drugs. Affymax`s proprietary approach to peptide architecture and delivery provides drug-like characteristics to peptides while preserving the specificity and potency advantages of peptides. Hematide(TM), a peptide-based erythropoiesis stimulating agent (ESA) being developed by Affymax, is currently in clinical trials for the treatment of anemia associated with chronic kidney disease, cancer and other diseases.

EntreMed President and Chief Executive Officer, James S. Burns said, "While EntreMed maintains its focus on Panzem(R) NCD and its IND-track product candidates, we remain committed to pursuing the potential for TFPI peptides in treating cancer. Collaborating with a recognized leader in the field of peptide discovery and development allows us to accelerate our TFPI program while concentrating our resources on later-stage programs."

Arlene M. Morris, President and Chief Executive Officer of Affymax commented on the collaboration, "TFPI peptides represent an attractive development approach for targeted cancer drugs. We look forward to combining our strength in peptide drug discovery and development with EntreMed`s strong knowledge in angiogenic inhibitors and expertise in oncology. We believe this collaboration is an excellent example of bringing together complementary expertise to rapidly advance both companies` objectives."

About Affymax

Affymax, Inc. is a development stage pharmaceutical company that is creating novel peptide drugs for the treatment of various blood, cancer and kidney diseases. Affymax is rapidly building a rich pipeline of novel peptide drugs against clinically validated targets that will provide superior product profiles over therapeutic proteins. Advantages of peptide-based drugs can include reduced immunogenicity, improved dosing convenience, greater stability and improved manufacturability. Hematide(TM), the Company`s first product to enter the clinic, is a peptide-based drug designed to stimulate the production of red blood cells. It is being developed for the treatment of anemia associated with chronic kidney disease and cancer. The Company is also advancing a peptide that is an agonist of the G-CSF receptor. For more information, visit the Company`s website at http://www.affymax.com/.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-Methoxyestradiol or 2ME2), the Company`s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for indications outside of oncology. EntreMed`s goal is to develop and commercialize new compounds based on the Company`s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases. The Company`s expertise has also led to the discovery of new molecules, including analogs of 2ME2, peptides of tissue factor pathway inhibitor (TFPI), and inhibitors of fibroblast growth factor-2 (FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering. For further information, visit EntreMed`s website at http://www.entremed.com/.

Forward Looking Statements

This release contains, and other statements that EntreMed may make may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are typically identified by words or phrases such as "believe," "feel," "expect," "anticipate," "intend," "outlook," "estimate," "target," "assume," "goal," "objective," "plan," "remain," "seek," "trend," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "might," "can," "may," or similar expressions. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and EntreMed assumes no duty to update forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in EntreMed`s Securities and Exchange Commission filings under "Risk Factors," including risks relating to EntreMed`s need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem(R); dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company`s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

[NOBODY_III]

09.11.2004 13:11:
EntreMed Reports Third Quarter 2004 Financial Results

ROCKVILLE, Md., Nov. 9 /PRNewswire-FirstCall/ -- EntreMed (Nachrichten), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammation, today reported results for the three and nine-month periods ending September 30, 2004.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2004 were approximately $143,000 versus $258,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.1 million), or ($0.09) per share. This compares with a net loss of approximately ($4.6 million), or ($0.15) per share for the same period last year.

For the nine months ending September 30, 2004, revenues were approximately $380,000 versus $1.1 million for 2003. Reported net loss for the first nine months of 2004 was ($12.4 million), or ($0.35) per share as compared to ($13.5 million) or ($0.51) per share for 2003.

Dane R. Saglio, EntreMed Chief Financial Officer commented, "The third quarter financial results demonstrate our continued progress in reducing non- research related costs. Going forward, we anticipate an increase in our research and development expenditures in order to support the Panzem(R) NCD clinical trials planned for early 2005."

The third quarter update call is scheduled for Wednesday, November 17, 2004 from 11:00 am to 12:00 pm ET and will include a question and answer session. To access the live conference, please dial 800-473-6123 (U.S. or Canada) or 973-582-2732 (internationally) at least 10 minutes prior to the beginning of the call. A digital recording will be available approximately one hour after completion of the conference and will be accessible for 60 days. To access the recording, dial 877-519-4471 (U.S. or Canada) or 973-341- 3080 (internationally) and enter the digital pin number 5364601. This call will not be web cast, however, an audio replay will also be available on the Company`s website at http://www.entremed.com/ approximately one hour after the conclusion of the live conference.

[ollihat]

Gestern wieder ein kräftiger Kursschub nach Norden!

Möglicher Auslöser eine Meldung der AP über weitere positive Ergebnisse mit Avastin von Genetech/Roche.
Bekanntlich ist Avastin angelegt, um den Blutzufluß zu stoppen, der Tumore ernährt.

Exakt das sollen ENMD`s potentielle Medikamente(Panzem) auch tun, die Bildung neuer Blutgefäße zum Tumor hin verhindern.
Wenn diese Methode wirklich erfolgversprechend ist bei der Tumorbekämpfung, dann kommt die kleine Entremed mal groß raus!

[ollihat]

Heute stärkster Prozentgewinner im Nasdaq, so far, versteht sich!

Was treibt den Kurs?

a. Entweder es gibt neue Forschungsergebnisse, die am Montag veröffentlicht werden;

b. oder einer der Lizenzpartner wie Elan oder Biogen bereiten ein Übernahmeangebot vor;

c. es gibt eine Adresse, die über mehr Infos verfügt wie der Rest der Anleger,

d. ein völlig durchgedrehter Börsenbrief empfiehlt: darüber habe ich keine Kenntnis.

Also, wo viel Rauch ist, muß auch ein Feuer sein!

[ollihat]

Stellungnahme von EntreMed:

"Thank you for your interest. We have not released any news and are not certain as to what is driving the volume of the stock today. The last public statement made by EntreMed was our 3Q04 update call which was conducted on November 17, 2004. There has been no news reported on behalf of the company since than.

As a publicly - traded company, it is our Practice to issue material news in form of a press release.

Regards Ginny Dunn"

Interessant finde ich ja die Formulierung:

We are not certain as to what is driving the volume . . .

Eine Vermutung will man aber nicht äußern.

[Mr.Arrogance]

Was treibt den Kurs?

a. Entweder es gibt neue Forschungsergebnisse, die am Montag veröffentlicht werden;

b. oder einer der Lizenzpartner wie Elan oder Biogen bereiten ein Übernahmeangebot vor;

c. es gibt eine Adresse, die über mehr Infos verfügt wie der Rest der Anleger,

d. ein völlig durchgedrehter Börsenbrief empfiehlt: darüber habe ich keine Kenntnis.


wenn man die erste handelsstunde heute betrachtet (über 50%-anstieg bei riesigen umsätzen), kann man ohne große gefahr behaupten, c. ist ganz sicher richtig.
wir haben heute das 20fache des normalen umsatzes, so phänomenal können neuigkeiten aus dem forschungsbereich nicht sein... und ein ganz überraschendes approval ohne antrag kann man wohl sicher ausschließen *lol*...
100%ig ohne relevanz ist punkt d.... da könnten sämtliche börsenbriefe der welt empfehlen.
punkt b. ist eher unwahrscheinlich, es sei denn CELG gibt sein jawort... mit CELG in zusammenhang stehen könnte der bemerkenswerte kursverlauf allerdings.

mr.A

[NOBODY_III]

Entremed heute in Amerika schon wieder 33 % im Plus!

Immer noch keine News zu den Hintergründen?

[ollihat]

Ich gehe davon aus, daß Panzem eine erfolgreiche Zukunft hat.

In der jüngeren Vergangenheit war immer wieder zu beobachten, daß ENMD einen Tag stark anstieg mit erhöhtem Volumen, die nächsten Tage liefen Umsätze und Kurse dann wieder zurück. Das deutet darauf hin, daß eine Adresse gezielt kauft.

Der jüngste massive Anstieg, den die Firma EntreMed ja nicht kommentiert hat, legt den Verdacht nahe, daß inzwischen mindestens eine zweite Adresse sehr interessiert ist an ENMD.

Deshalb läuft jetzt der Kurs weiter hoch!

[Mr.Arrogance]

heute noch mehr volumen... jetzt sind auch jede menge zocker mit drin, die gestern noch überrascht wurden in der ersten handelsstunde... heute fast das 30fache des durschn. umsatzes, d.h. wir haben in 2 tagen den free float gut einmal umgewälzt...

[Mr.Arrogance]

panzem ist ganz sicher nicht uninteressant... dennoch ist enmd als direktinvestment für mich ausschließlich ein zock. indirekt bin ich über celg investiert, und ich werde das gefühl nicht los, daß celg mit dem kursanstieg in verbindung steht... und die celg-macher haben anfang nov immerhin gut $25 mio locker gemacht, die müssen ja auch irgendwo hin.
aber alles reine spekulation, immerhin gab es zweimal in der enmd-history höhere kursanstiege mit noch größerem volumen... und es steckte kein buyout dahinter (obwohl der celg-deal aus 2003 dem nahe kommt).

[globalguru]

Das dürfte die Antwort auf den extremen Kursanstieg sein.
ENMD wurde vom "Leithammel-Report" empfohlen - wie lustig.

gruß

BellwetherReport.com Continues Tracking ENMD, TERN, SNDA, MSFT and Invites Shareholders to Take Part in Our Early Holiday Special!


NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.


TORONTO -- (MARKET WIRE) -- 12/12/04 -- The Bellwether Report will continue tracking Entremed (NASDAQ: ENMD), Terayon Communications (NASDAQ: TERN), Shanda Interactive Entertainment (NASDAQ: SNDA) and Microsoft (NASDAQ: MSFT), four companies that our subscribers have seen ample success with over the past 12 months.

Each of these companies will be placed in our proprietary tracking system for the ensuing 30 trading days to gauge their short-term trend and the shareholder sentiment.

The BWR Team would also like to take this time to wish you and your families a safe and enjoyable few weeks leading up to this holiday season and New Year.

As a gift from the Bellwether Report to you, we are offering shareholders of the above-mentioned companies a 45-day complimentary subscription to the Bellwether Report service.

We have identified the companies mentioned, as in each case they are companies that many of our current members have seen success with over the past year, and we hope that you are seeing that same success.

If you do wish to partake in our limited-time offer, and kick off the New Year right, feel free to visit www.BellwetherReport.com and sign up for 45 days free.

BWR is not affiliated or compensated by any of the above-mentioned companies.

The Bellwether Report scans the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on BWR or the above-mentioned companies feel free to sign up for a 45-day complimentary subscription to your #1 online investment resource www.BellwetherReport.com.

[Mr.Arrogance]

das dürfte mit 100%iger sicherheit nicht der grund sein...

[ollihat]

Im Yahoo Board schreibt einer:

"ENMD is the best bet on tumor shrinkage."

Das ist zumindest ein sehr guter Wunsch für 2005!
EntreMed war erfolgreich beim Tierversuch und bei ersten Tests am Menschen; aber vergessen wir nicht, daß auch andere Unternehmen daran arbeiten, die Blutversorgung zum Tumor zu unterbinden, als da sind Osi Pharmaceuticals oder auch Novartis zusammen mit Schering hier in Europa.

Das Interesse an der Aktie hat jedenfalls nicht nachgelassen, die Umsätze waren beachtlich in den Letzten Dezembertagen.

[ollihat]

EntreMed hat heute die Veröffentlichung einer Studie von einem erfolgreichen Tierversuch mit "Panzem" bekannt gemacht. Danach kann "Panzem" das Wachstum von Kopf- und Halstumoren wirksam einschränken.

300.000 Fälle dieser Krebsart bei Menschen werden in USA jährlich diagnostiziert.
Dabei ist es leider so, daß sich dieser Krebs dann schon in einem fortgeschrittenen Stadium befindet.

Ein wirksames "Panzem" wäre ein Durchbruch in der Therapie!

Das überzeugt viele Anleger: der Kurs macht einen Freudensprung auf 4$ !!